DIA Bioventure Day

Is the current Bioventure paradigm delivering return for patients and investors? This is the key question to be addressed by stakeholders from the funding, and from the innovating side.

戻る Agenda

Session 1: Health System Financing and Reimbursement of Innovation

Speaker(s)

Europe’s Flawed and Underfunded Biotech-Ecosystem (EBE position paper)

Barbara Freischem, DVM

European Medicines Agency, Netherlands

Head of Veterinary Surveillance and Regulatory Support Department

Is Parallel Micro-Innovation Overburdening the Health Care System?

Luca Pani, MD

University of Miami, United States

Former, AIFA; Professor, Department of Psychiatry and Behavioral Sciences

Links between Pharmaceutical R&D Models and Access to Affordable Medicines

Wija Oortwijn, PhD, MSc

Radboud University Medical Centre, Netherlands

Senior Scientific Researcher, Department for Health Evidence